Hercules Provides $15MM Term Loan to Zosano Pharma
Zosano Pharma, a clinical-stage specialty pharmaceutical company, announced it has secured $15.0 million in debt financing through Hercules Technology Growth Capital.
Zosano Pharma, a clinical-stage specialty pharmaceutical company, announced it has secured $15.0 million in debt financing through Hercules Technology Growth Capital.
Hercules Technology Growth Capital announced the appointment of Mark Harris as CFO of the company, effective August 1, 2015.
Hercules Technology Growth Capital announced Robert Lake joined the company as chief credit officer. Lake will report directly to Manuel A. Henriquez, chairman and chief executive officer of Hercules.
Hercules Technology Growth Capital is offering 6,600,000 shares of common stock pursuant to an effective shelf registration statement in an underwritten public offering.
Hercules Technology Growth Capital announced that effective March 7, 2015, Susanne D. Lyons, former chief marketing officer of Visa, was appointed to the Hercules board of directors.
Melinta Therapeutics announced that it entered into a $30 million debt financing agreement with Hercules Technology Growth Capital. Melinta has the option to draw an additional $10 million tranche in 2015.
Aspire Bariatrics closed on up to $12 million in venture debt financing with Hercules Technology Growth Capital.
BIND Therapeutics entered into an amendment of its existing credit facility from Hercules Technology III. Under the amendment, the company borrowed an additional $15 million in growth capital.
Cerulean Pharma entered into a loan and security agreement with Hercules Technology Growth Capital for a term loan of up to $26 million.
Dynavax Technologies said it has entered into a credit facility with Hercules Technology Growth Capital for up to $40 million of total funding.